All News
New: Classification Critiera and Recommendations in SpA
2026 EULAR Press Release
ASAS and the SPARTAN have updated their key classification criteria for axial SpA (axSpA). EULAR has also recently revised their recommendations on the role of imaging in the diagnosis and clinical management of spondyloarthritis (SpA). Both were presented at the EULAR 2026 annual Congress in London.
Read Article
JAK-SPARE: Ph3 RCT on baricitinib for rem induxn in early PMR.
BARI was effective vs. PBO in inducing & maintaining GC free rem.
No new safety signals.
New tx option for PMR (esp early). Decreases GC dependence & side effects.
LB0005 @RheumNow #EULAR2026 https://t.co/mWrr1RdPCm
Links:
sheila RHEUMarampa ( View Tweet)
#antisynthetase #EULAR/ACR #classification #criteria
#EULAR2026
@RheumNow
Based on >2k pts
Probable v definite
Ignore low + #synthetase #antibodies
Seems reasonable and applicable
➡️my opinion https://t.co/MyCRiCSiGo
Links:
Janet Pope Janetbirdope ( View Tweet)
LB0002: Sonelokimab (IL-17A/F Nanobody, ~40 kDa) in #axSpA Phase 2: 81% ASAS40 and 54% ASAS partial remission at 12 weeks. Mean ASDAS improvement of −2.0 from baseline. @RheumNow #EULAR2026 https://t.co/TjvtnFPCdj
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 Recommendations: Immunization (new since 2011)
- Vaccinate early regardless of dz acitiviry
- HBV booster/passive if poor response
- Yellow fever may be considered on individual basis
- Avoid live vaccines (mostly) in newborn exposed in utero to biologic
@RheumNow
Jiha Lee JihaRheum ( View Tweet)
#OP0209 #EULAR2026 SPECIFI-RA
Balinatunfib, oral selective TNFR1 inhibitor designed to preserve TNFR2 signalling in RA. Phase 2b trial missed primary ACR20 endpoint, but 200mg QD arm showed signals for higher ACR50, ACR70 and DAS28 low disease activity & reduced IL-6. @RheumNow https://t.co/emxNQy0cPx
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 #vaccination #guidelines
➡️be proactive
❎disease activity doesn’t matter
✅it is responsibility of #rheumatologist to discuss and update pt?
@RheumNow @eular_org https://t.co/dRnHd9CThg
Links:
Janet Pope Janetbirdope ( View Tweet)
Do you routinely recommend #herpes #zoster #vaccination in all #immune #suppressed pts?
#EULAR2026 @RheumNow
#vaccination #guidelines
Janet Pope Janetbirdope ( View Tweet)
#OP0207 #EULAR2026: SUPERFIBRES trial suggests dietary fibre supplementation may enhance MTX response in RA. Inulin improved EULAR responses and Th17/Treg balance over 30 days, with strongest effects seen in MTX-treated patients. Fascinating microbiome-linked signal. @RheumNow https://t.co/nCvZlooamF
Mrinalini Dey DrMiniDey ( View Tweet)
Data of #Rituximab
In #SARD-ILD
Small N of #RA-#ILD pts
I think data are sufficient as #RWE of #RTX in RA-ILD
✅benefits in other #CTD ILD
✅benefits in #rheumatoid #arthritis
#EVER-ILD #RCT
HOT #RA-ILD topic June 5
#EULAR2026
@RheumNow https://t.co/61MbsnNsaf
Links:
Janet Pope Janetbirdope ( View Tweet)
Is there enough data to recommend
#rituximab
For #ILD in #rheumatoid #arthritis
@RheumNow #EULAR2026
Janet Pope Janetbirdope ( View Tweet)
#OP0206 #EULAR2026: 🛴SCOOT trial compared oral split-dose vs SC MTX in early active RA. Non-inferiority of split-dose oral MTX was not shown, with several efficacy outcomes favouring SC MTX and more transaminitis seen with oral split dosing. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#OP0205 #EULAR2026: 🌞SUNSTAR head-to-head trial compared SC TOC vs Abatacept after failure of 1-2 b/tsDMARDs in RA. Primary CDAI endpoint was not met, but composite response and treatment persistence favoured tocilizumab. @RheumNow https://t.co/UepvKcbiNJ
Mrinalini Dey DrMiniDey ( View Tweet)
Effect of IL-17i on metabolic profile and CV safety in PsA/axSpA
169 pts 12mo
-IL-17i no MACE reported
-CRP reduced 4.8 → 2.9 mg/L, p<0.001
-79% systemic inflammatory response
-Lipids stable (LDL, TG, TC)
12mo follow up is probably too short though
#POS0375 #EULAR2026 https://t.co/u6cvB5YYGq
Aurelie Najm AurelieRheumo ( View Tweet)
#OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred oral JAKi over SC TNFi (55% vs 45%)
Importantly, own choice led to higher treatment satisfaction, better drug survival & fewer adverse events. @RheumNow #EULARBest https://t.co/iI1n2OGzqY
Mrinalini Dey DrMiniDey ( View Tweet)
Prospective study of RVZ immunogenicity = heterogeneous cellular immunity across RMDs
12mo 150 pts
-CD4+ gE-T-cell response peaks mo 3
-Response seen in axSpA + GCA, but not RA
-25% of patients no CMI increase after vaccination
Consistent w/other vaccine cellular imm profiles https://t.co/yvDLSHh4Bj
Aurelie Najm AurelieRheumo ( View Tweet)
#OP0203 #EULAR2026: low-dose blinatumomab in multidrug-resistant RA introduced the intriguing concept of “immune dimming”, transient B-cell depletion that appeared to restore responsiveness to previously failed DMARDs, JAK inhibitors and TNFi in several patients. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Frailty as a long term outcome in RA
Higher frailty in RA vs ctrls HR 1.76 in 910 matched pairs.
-10y: 30.6% vs 19.1%
-20y: 53.8% vs 35.3%
-Stronger in recent RA (HR 2.38)
Driven by age, smoking, comorbidity, steroids/biologics not RF/CCP.
Preventive interventions needed https://t.co/pcJrE73G5O
Aurelie Najm AurelieRheumo ( View Tweet)
TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials
8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis
Developed via multistage consensus process
Higher pt enrollment potential?
POS1068 @RheumNow #EULAR2026 https://t.co/W614xZV7TX
sheila RHEUMarampa ( View Tweet)
Catching up on #EULAR2026 “Advanced management in RA” session: #OP0202 reported positive phase 2b RENOIR data for rosnilimab, a selective pathogenic T-cell depleter, with significant improvements in DAS28-CRP, ACR responses and CDAI LDA vs placebo in RA. @RheumNow https://t.co/IKKtakxpya
Mrinalini Dey DrMiniDey ( View Tweet)
